Identification and molecular characterisation of proteins, expressed in the
The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have, said polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.
1. An isolated fusion protein which comprises an isolated polypeptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:36 fused to a heterologous polypeptide, said isolated polypeptide having a kunitz-type-protease-inhibitor (KPI) domain, wherein the KPI domain of the polypeptide comprises a Phe at a position corresponding to position 40 of SEQ ID NO:36, a Gly at a position corresponding to position 44 of SEQ ID NO: 36; a Cys at a position corresponding to position 45 of SEQ ID NO:36, a Phe at a position corresponding to position 52 of SEQ ID NO:36, and a Cys at a position corresponding to position 58 of SEQ ID NO:36.
2. The isolated fusion protein of claim 1 , wherein said polypeptide comprises at least one substitution group.
3. The isolated fusion protein of claim 1 , wherein said polypeptide is selected from the group consisting of a polypeptide having up to 3 amino acid substitutions relative to the amino acid sequence of SEQ ID NO: 36, a polypeptide having up to 3 amino acid deletions relative to the polypeptide of SEQ ID NO: 36, and a polypeptide having up to 3 amino acid additions relative to the polypeptide of SEQ ID NO: 36.
4. The isolated fusion protein of claim 1 , wherein said heterologous polypeptide comprises multiple histidine residues.
5. A diagnostic test kit comprising the isolated fusion protein of claim 1 .
6. The isolated fusion protein of claim 1 , wherein the polypeptide is a synthetic polypeptide.
7. The isolated fusion protein of claim 1 , wherein the polypeptide is non-glycosylated.
8. The isolated fusion protein of claim 1 , wherein the polypeptide is a recombinant polypeptide.
9. The isolated fusion protein of claim 2 , wherein the substitution group is a glycosyl group.
10. The isolated fusion protein of claim 1 wherein said polypeptide has the amino acid sequence of SEQ ID NO:36.
11. The isolated fusion protein of claim 1 , wherein said polypeptide has less than 100% and at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36.
12. A composition comprising the isolated fusion protein according to claim 1 , wherein the composition is immunogenic.
13. The composition of claim 12 , comprising an immunogenic amount of the isolated fusion protein.
14. The composition of claim 12 , wherein the composition comprises an adjuvant.
15. The isolated fusion protein of claim 1 , wherein the KPI domain comprises the amino acid sequence of amino acid residues 40 to 58 of SEQ ID NO:36.
16. The isolated fusion protein of claim 1 , further comprising a Cys at a position corresponding to position 12 of SEQ ID NO:36, a Cys at a position corresponding to position 21 of SEQ ID NO:36, a Cys at a position corresponding to position 37 of SEQ ID NO:36, and a Cys at a position corresponding to position 62 of SEQ ID NO:36.
17. The isolated fusion protein of claim 15 , further comprising a Cys at a position corresponding to position 12 of SEQ ID NO:36, a Cys at a position corresponding to position 21 of SEQ ID NO:36, a Cys at a position corresponding to position 37 of SEQ ID NO:36, and a Cys at a position corresponding to position 62 of SEQ ID NO:36.
18. A pharmaceutical composition comprising an adequate pharmaceutical carrier and the isolated fusion protein according to claim 1 .